As global markets react positively to the recent U.S.-China tariff suspension, Asian economies are witnessing a renewed sense of optimism, with key indices reflecting this upbeat sentiment. In such an environment, stocks with high insider ownership can be particularly appealing as they often indicate confidence from those closest to the company’s operations and potential growth trajectory.
Top 10 Growth Companies With High Insider Ownership In Asia
| Name | Insider Ownership | Earnings Growth |
| Schooinc (TSE:264A) | 26.6% | 68.9% |
| Nanya New Material TechnologyLtd (SHSE:688519) | 11% | 63.1% |
| Global Tax Free (KOSDAQ:A204620) | 20.8% | 35.1% |
| Fulin Precision (SZSE:300432) | 13.6% | 44.2% |
| M31 Technology (TPEX:6643) | 30.8% | 63.4% |
| Oscotec (KOSDAQ:A039200) | 21.1% | 85.9% |
| Zhejiang Leapmotor Technology (SEHK:9863) | 15.6% | 59.9% |
| giftee (TSE:4449) | 34.5% | 63.7% |
| Suzhou Sunmun Technology (SZSE:300522) | 35.4% | 77.7% |
| Techwing (KOSDAQ:A089030) | 18.8% | 65% |
We're going to check out a few of the best picks from our screener tool.
Ocumension Therapeutics (SEHK:1477)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Ocumension Therapeutics operates as an ophthalmic pharmaceutical platform company in the People's Republic of China, with a market cap of HK$5.56 billion.
Operations: The company's revenue primarily comes from its efforts in discovering, developing, and commercializing ophthalmic therapies, generating CN¥417.31 million.
Insider Ownership: 20.6%
Revenue Growth Forecast: 30.4% p.a.
Ocumension Therapeutics, with substantial insider ownership, is poised for significant growth. Its revenue is forecast to grow 30.4% annually, outpacing the Hong Kong market. Recent approval for a real-world study of OT-703 in China and expanding regional rights through an agreement with Alimera Sciences highlight its strategic initiatives. Despite past shareholder dilution and current losses, earnings are expected to grow 100.18% yearly, aiming for profitability within three years amidst high insider confidence.
- Navigate through the intricacies of Ocumension Therapeutics with our comprehensive analyst estimates report here.
- The valuation report we've compiled suggests that Ocumension Therapeutics' current price could be inflated.
NanJi E-Commerce (SZSE:002127)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: NanJi E-Commerce Co., LTD operates in China offering brand authorization, retail, and mobile Internet marketing services with a market cap of CN¥12.09 billion.
Operations: The company's revenue is derived from brand authorization, retail, and mobile Internet marketing services in China.
Insider Ownership: 28.9%
Revenue Growth Forecast: 18.2% p.a.
NanJi E-Commerce, with significant insider ownership, is set for promising growth despite recent challenges. Revenue is projected to grow 18.2% annually, surpassing the CN market average of 12.4%. However, the company reported a net loss of CNY 13.63 million in Q1 2025 compared to a profit a year ago and decreased its dividend payout. Earnings are expected to rise by 74.54% annually over three years, aiming for profitability amidst insider confidence and strategic revenue growth forecasts.
- Get an in-depth perspective on NanJi E-Commerce's performance by reading our analyst estimates report here.
- Our valuation report unveils the possibility NanJi E-Commerce's shares may be trading at a premium.
Hydsoft TechnologyLtd (SZSE:301316)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Hydsoft Technology Co., Ltd. offers professional IT services both in China and internationally, with a market cap of CN¥14.06 billion.
Operations: Hydsoft Technology Co., Ltd. generates revenue through its provision of professional IT services across domestic and international markets.
Insider Ownership: 24.1%
Revenue Growth Forecast: 24.3% p.a.
Hydsoft Technology Ltd. shows promising growth potential with earnings expected to grow significantly at 38.1% annually, outpacing the CN market's 23.7%. Revenue growth is also strong at 24.3% per year, exceeding market averages. However, profit margins have declined from last year and the company reported a drop in net income for Q1 2025 despite increased sales (CNY 505.76 million). High volatility in share price persists without substantial recent insider trading activity noted.
- Click to explore a detailed breakdown of our findings in Hydsoft TechnologyLtd's earnings growth report.
- Our valuation report here indicates Hydsoft TechnologyLtd may be overvalued.
Taking Advantage
- Unlock our comprehensive list of 625 Fast Growing Asian Companies With High Insider Ownership by clicking here.
- Want To Explore Some Alternatives? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Hydsoft TechnologyLtd might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com